\subsection{Anti-inflammatory activity}

\begin{table}[h]
\centering
\caption{Effect of test and standard compound on carrageenan-induced oedema}
\label{table_5}
\begin{tabular}{lccccc}
Comp. & Dose (mg/kg, p.o) & 0.0 h & 0.5 h & 1.0 h & 2.0 h \\
Control (N/saline) & 2.5/kg & 0.0 & 0.83$\pm$0.13 & 1.25$\pm$0.13 & 1.73$\pm$0.13 \\
3a & 50 mg/kg & 0.0 & 0.06$\pm$0.13** & 0.36$\pm$0.13** & 0.16$\pm$0.13** \\
3c & 50 mg/kg & 0.0 & 0.65$\pm$0.13* & 0.16$\pm$0.13** & 0.13$\pm$0.13** \\
4b & 50 mg/kg & 0.0 & 0.46$\pm$0.14** & 0.28$\pm$0.14** & 0.13$\pm$0.13** \\
5c & 50 mg/kg & 0.0 & 1.46$\pm$0.14 & 1.25$\pm$0.14 & 1.48$\pm$0.14 \\
6a & 50 mg/kg & 0.0 & 1.46$\pm$0.14 & 1.95$\pm$0.13 & 1.16$\pm$0.13 \\
6c & 50 mg/kg & 0.0 & 1.63$\pm$0.13 & 0.43$\pm$0.13 & 0.11$\pm$0.13 \\
7b & 50 mg/kg & 0.0 & 0.4$\pm$0.13** & 0.11$\pm$0.13** & 0.0$\pm$0.13** \\
8a & 50 mg/kg & 0.0 & 1.5$\pm$0.13 & 1.23$\pm$0.14 & 0.6$\pm$0.13 \\
8c & 50 mg/kg & 0.0 & 0.18$\pm$0.14** & 0.51$\pm$0.13** & 0.28$\pm$0.13* \\
Std. (diclofenac) & 50 mg/kg & 0.0 & 0.4$\pm$0.14** & 0.2$\pm$0.13** & 0.51$\pm$0.14** \\
\end{tabular}
\end{table}

The statistical significance of differences assessed with an analysis of variance (ANOVA), followed by Bonferroni t-test test. Results are expressed in mean $\pm$ SEM. (N=6) significance levels *P$<$0.05 and **P$<$0.01, compared with control respectively.

\begin{figure}[h]
\centering
\includegraphics{figure_3.pdf}
\caption{Effect of test and standard compound on carrageenan-induced oedema.}
\label{figure_3}
\end{figure}

\section{RESULT AND DISCUSSION}

\subsection{Antimicrobial activity}

Derivatives of 1-methyl-4(5-(4-(phenyl amino) phenyl)-1,3,4-thiadiazol-2-e thiosemicarb azide (2a-f) were reacted with corresponding reactant dimity lamina, morph line and piper dine (a-c) in the presence of formaldehyde and concentrated acid. All synthesized compounds were obtained in the range of 57.41--66.7\% yield. Purity and homogeneity of the synthesized compound were routinely checked by sharp melting point and TLC. Melting point of the all synthesized compound was observes between at 240.0--251.0$^{\circ}$C.

57.41--66.7 \% yield purity and homogeneity of the synthesized compound were routinely checked by sharp melting point and TLC. melting point of the all synthesized compounds was observed 240.0--251.0$^{\circ}$C.

The \textit{in vitro} antimicrobial activity of the synthesized compound was evaluated by cup plate method for bacteria viz. \textit{S. aureus}, \textit{B. subtilis}, \textit{E. coli}, \textit{K. pneumoniae} and fungi \textit{C. albicans}, \textit{A. Niger}. .some compounds exhibited potent pharmacological activities as compared to the standard drugs.

The compounds 3b and 4a exhibited highest activity i.e. each with 82.60\% inhibition against \textit{S. aureus} while the compound 4b, 5b, 6b, 7c showed 65.21, 69.56, 52.17 and 52.17\% inhibition respectively against \textit{S. aureus}. Against \textit{B. subtilis} the compound 3a, 3b, and 4c showed 85.71, 95.23, 66.66\% inhibition respectively and were the highest activity compound. While the compound for 4a, 5a, 6c, 8b (each with 57.41\% inhibition) and 5b (47.61\% inhibition) showed activity.

When tested against \textit{E. coli} the compound 3c, 4a, 6b, 7a and 7c exhibited 60.86, 52.17, 52.17, 52.17 and 60.86\% inhibition respectively and these compound showed Good activity among the tested compound. The highest activity was observed with 8c (with 69.56\% inhibition).

Against \textit{K. pneumoniae} the compound 3b (65.21\%), 4c (60.86\% inhibition), 5a (60.86\% inhibition), 7a (65.21\% inhibition), 7b (65.21\% inhibition) and 7c (65.21\% inhibition) exhibited good activity. Among the highest ac tested compounds 3a (69.56\%) showed activity.

All the synthesized compound were screened \textit{in vitro} against the pathogenic fungal strains \textit{A. niger} and \textit{C. albicans}. The compound 3a (68.42\% inhibition), 5a (73.68\% inhibition), 5c (63.15 inhibition), 6b, 7b (each with 63.15\% inhibition) and 8a (68.42\% inhibition) showed excellent activities.